Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Sinovac Biotech (SVA): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow SVA for free
Share

Sections with a free account

1 concentrated manager holds it with a median weight of 3.5%.

Who owns Sinovac Biotech?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): 1Globe Capital, 32.3% (13D/A filed Jan 30, 2026), SAIF Partners IV, 15.0% (13D/A filed Jan 30, 2026), Weidong Yin, 8.9% (13D/A filed Jul 15, 2025), Advantech Capital, 8.1% (13D/A filed Jul 14, 2025) and Vivo Capital IX, 6.3% (13D/A filed Jul 11, 2025). As of Jun 30, 2026, the largest holders reported on Form 13F were Vivo Capital (8.2% of the shares), Orbimed Advisors (3.8%) and Neumann Advisory Hong Kong (0.4%).

Which institutions hold the most Sinovac Biotech shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. Vivo Capital: 8.2%
  2. 2. Orbimed Advisors: 3.8%
  3. 3. Neumann Advisory Hong Kong: 0.4%
  4. 4. Susquehanna International Group, LLP: 0.0%
  5. 5. Morgan Stanley: 0.0%
  6. 6. Wells Fargo: 0.0%
  7. 7. UBS Group: 0.0%
  8. 8. Harbour Investments: 0.0%
  9. 9. Horizon Investments: 0.0%

How much of Sinovac Biotech do institutions own?

The 9 institutions that file 13F reported 12.5% of the shares as of Jun 30, 2026.

Sources:13D/A by 1Globe Capital (Jan 30, 2026) ↗13D/A by SAIF Partners IV (Jan 30, 2026) ↗13D/A by Weidong Yin (Jul 15, 2025) ↗13D/A by Advantech Capital (Jul 14, 2025) ↗13D/A by Vivo Capital IX (Jul 11, 2025) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Dec 31, 2025). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Sinovac Biotech revenue

Sinovac Biotech reported annual revenue of $386.0 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 20-F filed with the SEC (XBRL data).

Concentrated managers
1
All 13F: 9
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$6.47
-0.0% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (1 → 1): 0 opened · 0 exited = 0

Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of SVA (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 12.5% of the shares · top 10: 12.5%

Share of the stock held by 13F filers

Q2 2026: 12.5%

16.4%3.0%
Q4 2021Q2 2026

Shares reported by the 9 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Dec 31, 2025). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

12-month figures to Dec 31, 2025 · balance sheet as of Dec 31, 2025.

Profitability
Operating margin
-127.0%
Net margin
-15.5%
ROE
-1.3%
Growth
Revenue (TTM)
$386M
Revenue growth
6.8%
Net income (TTM)
$-59.7M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
$-561M
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 71.9 M

113.7 M0
20162025
1 year
0.0%
3 years
+0.1%
5 years
−36.8%
Buybacks (FY 2025)
no data
Share issuance
$0
Stock-based compensation
$00.0% of revenue
Dividends paid
$3.5 bn

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
no data
Debt due within 12 months
$229M0.04 times cash and investments
Debt maturities by year (note as of Dec 31, 2025)
  • Year 1$229M
  • Year 2$61.8M
  • Year 3$3.7M
  • Year 4$5.1M
  • Year 5$23.1M
  • Later$172M

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
no data
Amount (6 m)
no data
CEO/CFO bought (12 m)
No

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • 1Globe Capital32.3%13D · amendmentfiling ↗Event: Sep 10, 2025 · filed: Jan 30, 2026
  • SAIF Partners IV15%13D · amendmentfiling ↗Event: Dec 15, 2025 · filed: Jan 30, 2026
  • Weidong Yin8.85%13D · amendmentfiling ↗Event: Jul 10, 2025 · filed: Jul 15, 2025

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow SVA for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow SVA